Colorectal cancer (CRC) is a major cause of cancer death. In spite of progress in CRC treatment in last decades using surgery, chemotherapy, radiotherapy and target therapy approach, the metastatic disease, especially incurable, has an unfavorable prognosis. The introduction of immunotherapy-associated strategies: active, adoptive andimmune checkpoint inhibitors — to the treatment of CRC isintended to overcome the limits of classical therapy. We review the current state of the art for immunotherapy of CRC, such as the use of dendritic cell-, peptide-, tumour-derived, DNA-vaccines, viral vector vaccines, cell therapy, oncolytic viral therapy, immune checkpoint inhibitors in the light of perspectives for further improvements for clinical application.